Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Publishes | Twice weekly | Episodes | 545 | Founded | 17 years ago |
---|---|---|---|---|---|
Number of Listeners | Categories | Health & FitnessMedicineScience |
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma.
NCPD information and select publications here.
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.
CME informat... more
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Te... more
Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma.
NCPD information and select publications here.
People also subscribe to these shows.
That is how I feel about Dr Neil Love and his tireless work in continuing medical education for everyone in the medical field. These podcasts and discussions contained are informative, thought provoking and provide and excellent in depth but quick update in the rapidly ever-changing field of Hematology-Oncology.
Always informative, always applies to those of us on the ground making difficult daily decisions on management in the community. Often with limited resources.
I
Key themes from listener reviews, highlighting what works and what could be improved about the show.
How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.
Apple Podcasts | #84 | |
Apple Podcasts | #111 | |
Apple Podcasts | #138 | |
Apple Podcasts | #212 |
Recent interactions between the hosts and their guests.
Listeners, social reach, demographics and more for this podcast.
Listeners per Episode | |
---|---|
Gender Skew | |
Location | |
Interests | |
Professions | |
Age Range | |
Household Income | |
Social Media Reach |
This series focuses on advancements in the treatment of hematologic cancers, featuring interviews with leading experts in the field. Each episode provides in-depth discussions about novel therapies, clinical findings, and management strategies relevant to conditions such as non-Hodgkin lymphoma, multiple myeloma, and leukemias. Notable elements include real-world experiences shared by medical oncologists and the emphasis on tailored treatment approaches to improve patient outcomes. With a commitment to disseminating cutting-edge information, this series serves as a vital resource for healthcare professionals navigating the rapidly evolving landscape of hematologic oncology.
Rephonic provides a wide range of podcast stats for Hematologic Oncology Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Hematologic Oncology Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.
Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Hematologic Oncology Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.
Rephonic provides comprehensive predictive audience data for Hematologic Oncology Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.
To see how many followers or subscribers Hematologic Oncology Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.
These podcasts share a similar audience with Hematologic Oncology Update:
1. Two Onc Docs
2. Blood Cancer Talks
3. Blood Podcast
4. Oncology Today with Dr Neil Love
5. The Hematologist
Hematologic Oncology Update launched 17 years ago and published 545 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.
Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.
Rephonic pulls ratings and reviews for Hematologic Oncology Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.
View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.
Rephonic provides full transcripts for episodes of Hematologic Oncology Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.
Recent guests on Hematologic Oncology Update include:
1. Dr. Neel Pasricha
2. Charise Gleason
3. Thanos Dimopoulos
4. Bob Orlowski
5. Dr. Rafael Fonseca
6. Dr. Jennifer Crombie
7. Dr. John P. Leonard
8. Dr. Raajit K Rampal
To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.